Skip to main content

Table 2 BAL fluid analysis

From: Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial

  Placebo Fluticasone Fluticasone/Salmeterol
Time point A B A B A B
n 14 14 14 14 14 14
Recovery (ml BAL fluid) 62 (45 - 67) 64 (48 - 71) 63 (56–70) 65 (37–72) 62 (55–65) 62 (54–70)
Total cells (10 3 /ml BAL fluid) 121 (17–487) 190 (35–469) 81 (38–284) 93 (6–217) 125 (36–409) 97* (25–339)
Macrophages (10 3 /ml BAL fluid) 114 (15–447) 181 (34–459) 75 (32–263) 86 (5–205) 119 (32–397) 88* (22–315)
Lymphocytes (10 3 /ml BAL fluid) 7.2 (0.5 - 34.1) 5.6 (0.7 - 28.2) 2.7 (0.6 - 13.1) 4.1 (0.6 - 7.8) 3.0 (1.0 - 39.1) 3.2 (0.7 - 14.2)
Neutrophils (10 3 /ml BAL fluid) 2.1 (0.3 - 12.0) 1.4 (0.0 - 5.0) 1.6 (0.6 - 5.1) 1.2 (0.2 - 6.1) 2.9 (0.1 - 5.4) 0.7* (0.0 - 6.1)
Eosinophils (10 3 /ml BAL fluid) 0.4 (0.0 - 5.1) 0.3 (0.0 - 4.2) 0.5 (0.0 - 2.8) 0.2 (0.0 - 1.2) 0.1 (0.0 - 3.0) 0.2 (0.0 - 3.4)
  1. Shown are median values (minimum – maximum) of the recovery of BAL fluid, the total concentration of BAL fluid cells and the concentrations of macrophages, lymphocytes, neutrophils and eosinophils in BAL fluid of the participants (median values, minimum – maximum) in the 3 study arms (Placebo, Fluticasone, Fluticasone/Salmeterol), at the time points A (prior to treatment) and B (directly after treatment). Significant differences between the time points (p < 0.05) are marked with an asterisk (*).